Another Legal Setback for Myriad

A judge declines Myriad Genetics’s request to block its competitors from selling BRCA tests.  

By | March 11, 2014

WIKIMEDIA, HAKUNAMATATA1Myriad Genetics, a Utah-based genetic diagnostics firm, has tried to get the courts to stop its competitors from selling kits that test for the cancer-associated BRCA mutations. But a U.S. District Court judge this week (March 10) denied the injunction because Myriad’s patent claims may not hold up in an ongoing lawsuit.

Charles Dunlop, the CEO of Ambry Genetics, one of the firms being sued by Myriad, called the decision “exhilarating.” He said in a statement that “competition stemming from a free market drives all of us to improve and ultimately increases patient access to life-changing information.”

In his decision, Judge Robert Shelby took issue with Myriad’s patenting practices in general. He wrote that “the practical result of Myriad’s patents has been to hinder or halt follow-up research, data sharing, patient testing, and the creation of additional and more affordable technologies for BRCA1 and BRCA2 testing.” Myriad spokesman Ron Rogers told Bloomberg News that “Myriad did not block or hinder research; in fact that opposite is true. A strong patent system made that all possible.”

Last year, the Supreme Court ruled that Myriad could not patent the BRCA1 and BRCA2 genes. Shortly after, other companies began to offer BRCA tests. Myriad, along with the University of Utah, the University of Pennsylvania, the Hospital for Sick Children, and Endorecherche, swiftly responded with lawsuits against Ambry, Gene by Gene, and other companies, claiming they infringed on Myriad’s patents. While the lawsuits involving Ambry and others are ongoing, Gene by Gene settled out of court.

“It is important to maintain perspective,” Rogers told GenomeWeb Daily News. “The ruling is a denial of the preliminary injunction only and it isn't a ruling on the underlying merits of the case. We remain in the early stages of the litigation and look forward to presenting our case in court.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech